Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > BUSINESS
BUSINESS
- Merck Serono Obtains Marketing Rights for Cetrotide from Shionogi
April 22, 2013
- AnGes MG, Shionogi to Start PI Study for Nucleic Acid Drug for Atopic Dermatitis
April 19, 2013
- Daiichi Sankyo to Enter Branded Generics Business in Brazil with Launch of 2 Products
April 19, 2013
- Eli Lilly Japan Aims to Be a Top-10 Drug Maker in Japan by 2020, but Re-pricing and Generic Competition Could Pose Obstacles
April 19, 2013
- Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
- Taisho, Nissui Launch Switch OTC Epadel; Prior Doctor Consultation Required for Patients
April 18, 2013
- Meiji Seika Pharma Licenses Schizophrenia Treatment from MSD, to Market It Independently
April 18, 2013
- Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
- Pfizer’s Palbociclib Receives Breakthrough Therapy Designation from US FDA
April 18, 2013
- Teijin, Kyorin Expected to Grow thru “Win-Win” Relationship: Teijin Pharma Pres.
April 17, 2013
- Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
- BMKK Sales Up 13% to 62 Billion Yen in 2012
April 17, 2013
- Nearly 43% of Pharmacies Now Receive Class 3 Fee for Generic Drug Dispensing Systems: Survey
April 17, 2013
- Astellas Appoints Dr Xue as Head of GPV
April 17, 2013
- FDA Accepts Otsuka Tolvaptan NDA for Priority Review
April 17, 2013
- Chugai Voluntarily Recalls Digosin Tablets
April 16, 2013
- Toho Holdings Establishes New Company for Distribution Management of Specialty Drugs
April 16, 2013
- MAA for Lurasidone Accepted in Australia: DSP
April 16, 2013
- Hisamitsu Sales Up 3.6% Helped by Mohrus Tape Sales Recovery
April 15, 2013
- Over Half of Domestic, Foreign-Affiliated Drug Makers Hired Fewer New Graduates This Year: Survey
April 15, 2013
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…